Sort   by:  
 Page size 
UnknownImpact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.
Not available
S-EPMC11494165 | biostudies-literature
UnknownDivergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.
Not available
S-EPMC11514147 | biostudies-literature
UnknownOverall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
Not available
S-EPMC10022857 | biostudies-literature
UnknownTeclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
Not available
S-EPMC10402759 | biostudies-literature
UnknownLonger term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Not available
S-EPMC8597112 | biostudies-literature
UnknownTherapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma.
Not available
S-EPMC9519052 | biostudies-literature
UnknownThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.
Not available
S-EPMC7359060 | biostudies-literature
UnknownEarly alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
Not available
S-EPMC6629164 | biostudies-literature
UnknownCorneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
Not available
S-EPMC7708586 | biostudies-literature
UnknownDaratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.
Not available
S-EPMC7012498 | biostudies-literature
Sort   by:  
 Page size